Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Author: FormBlends Editorial
Key Takeaways
- Ozempic is FDA-approved only for adults 18 and older with type 2 diabetes
- Wegovy (semaglutide for obesity) is FDA-approved for adolescents 12 and older with BMI at or above the 95th percentile for age and sex (approval June 2023)
- Mounjaro and Zepbound (tirzepatide) remain adult-only as of May 2026
- No formal upper age limit, but patients over 75 generally require lower doses and slower titration
- Off-label pediatric Ozempic use exists but is uncommon and typically confined to specialist settings
Direct answer
Ozempic is FDA-approved for adults 18 and older. The drug has not been studied for safety or efficacy in patients under 18 and is not approved for pediatric use. The closest pediatric option is Wegovy, which is the same active ingredient (semaglutide) approved at obesity-focused dosing for adolescents 12 and older with BMI at or above the 95th percentile for age and sex. Adolescents seeking GLP-1 therapy should be evaluated by pediatric specialists, not adult-focused telehealth platforms.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Ozempic age requirement
- Wegovy pediatric approval
- The STEP TEENS evidence base
- Mounjaro and Zepbound age rules
- Pediatric obesity treatment context
- Off-label pediatric Ozempic use
- Older adults: practical considerations
- How telehealth platforms screen for age
- Contrary view: should pediatric access be wider
- Decision framework by age
- FAQ
- Sources
Ozempic age requirement
The Ozempic label specifies use in adults with type 2 diabetes. "Adult" in FDA labeling means 18 years of age or older. The pediatric population has not been studied for Ozempic, and the prescribing information explicitly notes that safety and efficacy in patients younger than 18 have not been established.
The reason Ozempic was not extended to pediatric type 2 diabetes is partly numerical: pediatric type 2 diabetes is much less common than adult-onset, so trial recruitment is harder and commercial incentive is lower. Novo Nordisk concentrated pediatric semaglutide development on the obesity indication (Wegovy) where the pediatric population is larger and the clinical pathway clearer.
Wegovy pediatric approval
The FDA approved Wegovy for adolescents in June 2023. The approval covers patients aged 12 and older with:
- Initial BMI at or above the 95th percentile for age and sex (the pediatric definition of obesity), AND
- Body weight greater than 60 kg
The approval is for use as an adjunct to a reduced-calorie diet and increased physical activity. Wegovy was the first weekly GLP-1 medication approved for pediatric obesity. Saxenda (daily liraglutide) had earlier approval for adolescents 12+ from December 2020.
Dosing in the pediatric population follows the same escalation schedule as adults, with the same target dose of 2.4 mg weekly. Many pediatric specialists titrate more slowly to manage tolerance.
The STEP TEENS evidence base
The pivotal pediatric trial was STEP TEENS (Weghuber et al. 2022, NEJM). Design summary:
- Population: 201 adolescents aged 12-17 with obesity (BMI at or above the 95th percentile)
- Mean baseline BMI: 37
- Intervention: semaglutide 2.4 mg weekly versus placebo, both with lifestyle counseling
- Duration: 68 weeks
- Primary outcome: percentage change in BMI
Results: mean BMI reduction of 16.1% in the semaglutide group versus 0.6% gain in placebo. About 73% of adolescents on semaglutide achieved at least 5% body weight loss, compared with 18% on placebo. Side effect profile mirrored adult trials: gastrointestinal symptoms dominated, mostly mild to moderate, decreasing over time.
The trial supported FDA expansion. Longer-term data on growth, puberty timing, and bone density in adolescent users remain under post-marketing surveillance.
Mounjaro and Zepbound age rules
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is approved only for adults 18 and older as of May 2026. Eli Lilly has active pediatric programs:
- SURMOUNT-T2D: tirzepatide in pediatric type 2 diabetes, results expected 2026-2027
- SURMOUNT-PEDS: tirzepatide in pediatric obesity, results expected 2026-2027
Pediatric expansion is plausible but not guaranteed. The clinical and regulatory pathway is similar to the semaglutide pediatric expansion that succeeded for Wegovy.
Pediatric obesity treatment context
The American Academy of Pediatrics published a 2023 clinical practice guideline on obesity management in children and adolescents. Key points relevant to GLP-1 medications:
- Intensive health behavior and lifestyle treatment remains foundational
- Pharmacotherapy can be considered for adolescents 12+ with obesity, alongside lifestyle intervention
- Metabolic and bariatric surgery is an option for adolescents 13+ with severe obesity (BMI at or above the 120th percentile or BMI 35+)
- Family involvement, motivational interviewing, and screening for eating disorders are emphasized
The AAP guideline was controversial. Critics argued it could medicalize normal variations in adolescent body size; supporters argued that pediatric obesity prevalence (over 19% of US children and adolescents in 2024 CDC data) demands more aggressive treatment options. The balanced clinical position: pharmacotherapy is appropriate for adolescents who meet criteria, with rigorous specialist evaluation and family-involved care.
Off-label pediatric Ozempic use
Off-label Ozempic prescribing in adolescents occurs but is uncommon. The scenarios where it might appear:
- A pediatric endocrinologist treating an adolescent with type 2 diabetes who needs glycemic control; the family or insurance prefers Ozempic dosing
- An adolescent with obesity for whom Wegovy supply is unavailable and the specialist substitutes semaglutide via Ozempic
- Rarely, a young-adult patient (18-24) where the choice between Ozempic and Wegovy is driven by insurance coverage
Off-label pediatric prescribing should occur in a specialist setting with appropriate family consent and monitoring. It is not appropriate through general adult-focused telehealth platforms.
Older adults: practical considerations
There is no formal upper age limit on Ozempic or other GLP-1 medications. Practical considerations for patients over 65:
| Consideration | Impact |
|---|---|
| Gastrointestinal tolerance | Older patients report more nausea and tend to discontinue at higher rates |
| Dehydration risk | Reduced thirst sensation plus GI losses can produce kidney injury |
| Sarcopenia | GLP-1 weight loss includes 25-40% lean mass; sarcopenic patients should prioritize protein and resistance training |
| Polypharmacy | More drug interactions, more medications affected by delayed gastric emptying |
| Falls risk | Weight loss can shift center of gravity and balance; gait monitoring matters |
Patients over 75 generally start at 0.25 mg weekly with slower titration (8-week intervals instead of 4) and closer follow-up. Frail elderly patients with significant sarcopenia or recent falls may not be appropriate candidates regardless of BMI.
How telehealth platforms screen for age
Reputable telehealth GLP-1 platforms typically:
- Require age 18+ for patient enrollment
- Verify age through government ID or attestation with date of birth
- Decline patients under 18 with referral to pediatric specialist care
- Set upper age cutoffs (often 75 or 80) above which more rigorous medical workup is required
Platforms that accept pediatric patients without specialist coordination should be treated with skepticism. Adolescent obesity care requires growth monitoring, puberty staging, family involvement, and coordination with the patient's pediatrician. Adult-focused telehealth is not the right setting.
Contrary view: should pediatric access be wider
Some arguments for expanding pediatric GLP-1 access:
Pediatric obesity is a serious chronic disease. Adolescent BMI strongly predicts adult cardiometabolic outcomes. Intervening earlier may prevent long-term complications. Restricting pharmacotherapy to those who fail lifestyle change first may delay treatment when biology is most modifiable.
The STEP TEENS data are strong. A 16.1% BMI reduction in adolescents is clinically meaningful. Side effects mirror adults and are largely manageable.
Counter-arguments:
Long-term pediatric safety data are limited. Effects on growth, puberty, bone density, and adult metabolism are still being characterized. Caution is appropriate when treating a developing body.
Eating disorder risk. Adolescence is the highest-risk window for new-onset eating disorders. Introducing appetite-suppressing medication during this developmental period requires careful screening.
Lifestyle intervention has lasting benefit. Early pharmacotherapy may shift focus away from family habits, school food environment, sleep, and activity, which have benefit beyond weight.
The current balance, treating pharmacotherapy as one option in a multi-component pediatric obesity program, reflects both the strength of trial data and the need for cautious surveillance.
Decision framework by age
Under 12: No FDA-approved GLP-1 option. Lifestyle, family-based care, and pediatric specialist coordination are the standard.
Age 12-17 with BMI at or above 95th percentile: Wegovy is FDA-approved. Saxenda is also approved (daily liraglutide). Pediatric endocrinology or family medicine with adolescent obesity expertise is the appropriate setting.
Age 18-65: All GLP-1 medications are options for FDA-approved indications. Telehealth pathway is appropriate for many patients.
Age 65-75: All GLP-1 medications remain options, but more conservative titration and closer monitoring are typical.
Age 75+: No formal exclusion, but evaluate sarcopenia, falls risk, dehydration risk, and polypharmacy carefully. Lower starting doses and slower titration are standard.
FAQ
How old do you have to be to take Ozempic? 18 or older. Ozempic is FDA-approved only for adults with type 2 diabetes. Pediatric obesity patients age 12+ have access to Wegovy (semaglutide for obesity).
Can a 16-year-old take Ozempic? Not on label. A 16-year-old with severe obesity might qualify for Wegovy. Off-label Ozempic in adolescents is uncommon and specialist-driven.
Can children take Ozempic for weight loss? Children under 12 are not approved for any GLP-1 medication. Wegovy starts at age 12 with BMI at or above the 95th percentile.
Is there an upper age limit for Ozempic? No formal limit. Patients over 75 typically need lower starting doses, slower titration, and closer monitoring for dehydration and sarcopenia.
Why is Wegovy approved for younger patients but Ozempic is not? Same molecule, different indication and dose. Novo Nordisk pursued pediatric studies for the obesity indication; pediatric type 2 diabetes is smaller and was not pursued.
What pediatric obesity trial supports the Wegovy approval? STEP TEENS (Weghuber et al. 2022, NEJM): 16.1% mean BMI reduction in adolescents aged 12-17.
Can a teenager get GLP-1 medication through telehealth? Most reputable platforms require age 18+. Adolescent obesity care should occur in a pediatric specialist setting.
Is Mounjaro or Zepbound approved for adolescents? Not as of May 2026. Eli Lilly pediatric trials are underway with results expected 2026-2027.
Sources
- FDA. Wegovy Prescribing Information, June 2023 Pediatric Approval Update.
- FDA. Ozempic Prescribing Information. Current revision 2025.
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). NEJM. 2022.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023.
- FDA. Saxenda Prescribing Information, Pediatric Approval. December 2020.
- Centers for Disease Control and Prevention. Childhood Obesity Facts. Updated 2024.
- Eli Lilly. SURMOUNT-PEDS and SURMOUNT-T2D Clinical Trial Registry Entries. ClinicalTrials.gov. Accessed 2026.
- American Society for Metabolic and Bariatric Surgery. Pediatric Metabolic and Bariatric Surgery: Updated Recommendations. 2023.
- Endocrine Society. Pediatric Obesity Pharmacotherapy: Clinical Practice Guideline. 2024.
- FDA Adverse Event Reporting System (FAERS). Pediatric Semaglutide Surveillance Summary, 2024-2025.
Footer disclaimers
Platform Disclaimer. FormBlends is an adult telehealth platform. We do not treat patients under 18. Pediatric obesity care requires specialist-led evaluation outside our scope. Adult patients are connected to independent licensed clinicians.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved and are not interchangeable with brand medications. They are prepared by 503A pharmacies in response to individual prescriptions. Compounded medications are not appropriate for pediatric use through our platform.
Results Disclaimer. Trial outcomes cited (STEP TEENS, STEP 1) reflect average study results. Individual response varies. Pediatric outcomes may differ from adult outcomes in ways still being characterized through post-marketing surveillance.
Trademark Notice. Wegovy, Ozempic, and Saxenda are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. FormBlends is independent of these manufacturers.